dc.contributor.author |
Jayasinghe, Manori |
|
dc.contributor.author |
Srilal, Thotawaththage Loshadhi Indunika |
|
dc.contributor.author |
Prasadi, Deweni Guruge Pathmila |
|
dc.contributor.author |
Madushika, Wickramasinghe Senanayakege Sachini |
|
dc.contributor.author |
Silva, Samanda Marakkala Dileka Udyani |
|
dc.contributor.author |
Subasinghe, Sewwandi |
|
dc.date.accessioned |
2023-01-10T05:33:20Z |
|
dc.date.available |
2023-01-10T05:33:20Z |
|
dc.date.issued |
2022-03-01 |
|
dc.identifier.citation |
Jayasinghe, M., Srilal, T.L.I., Prasadi, D.G.P. et al. Regulatory requirements and labeling of commercially available prescription (oral) medicines in Sri Lanka: there is room for improvement. J of Pharm Policy and Pract 15, 13 (2022). https://doi.org/10.1186/s40545-022-00409-z |
en_US |
dc.identifier.issn |
2052-3211 |
|
dc.identifier.uri |
http://ir.lib.ruh.ac.lk/xmlui/handle/iruor/10126 |
|
dc.description.abstract |
Background: The consistency and the quality of medicine labels are sought through the regulatory frameworks. This
study aims at investigating the secondary labels of medicines based on the labeling regulations and guidelines issued
by the National Medicines Regulatory Authority (NMRA), Sri Lanka.
Methods: A descriptive cross-sectional study was conducted on 53 commonly used prescription-only oral medicines
selected using the price regulations published for most commonly used drugs. High-resolution images of 216 brands/
branded generics/generic products’ secondary labels were collected in April 2021 from six community pharmacies
in six districts chosen as a convenience sample. Each label was manually assessed using a checklist prepared based
on the regulatory requirements by four trained investigators. The status of registration of each product was assessed
using the NMRA website. Descriptive statistics were performed.
Results: There was a variation observed in labeling regulations and information present on packages. Among the
216 products evaluated, only 148 (68%) products appeared as registered medicines on the NMRA website, and 2.3%
of medicines fulflled all stipulated labeling parameters set out by the NMRA, 3% of products abided by the general
labeling requirements, and 76% of the products complied with labeling requirements for API. Major defciencies were
observed in the presentation of registration numbers and the details of the local agent, which were unaccounted for
in 210 (97%) and 131 (61%) products, respectively. The highest consistency (100%) of information was noted with the
dosage form, date of manufacture, date of expiry, and batch numbers. Among the restricted information, attractive
pictures (2%), web addresses (6%), and over-stickers (34%) were found.
Conclusions: The results highlighted a gap between regulatory requirements and practice in medicine labeling
information. Regular post-market examination of medicinal labels is highly advised in a country that relies largely on
imports. Similarly, careful adherence to the labeling regulations is required. Furthermore, suppliers and local agentsshould be held accountable for ensuring accurate medicine labeling through increased awareness, education, and
sanctions. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
BMC |
en_US |
dc.subject |
Policy |
en_US |
dc.subject |
Labeling of drugs |
en_US |
dc.subject |
Regulations |
en_US |
dc.subject |
National Medicines Regulatory Authority |
en_US |
dc.subject |
NMRA |
en_US |
dc.subject |
Medication errors |
en_US |
dc.subject |
Safe use of medicines |
en_US |
dc.subject |
Medicine label information |
en_US |
dc.subject |
Medicine packaging |
en_US |
dc.title |
Regulatory requirements and labeling of commercially available prescription (oral) medicines in Sri Lanka: there is room for improvement |
en_US |
dc.type |
Article |
en_US |